Priority Lists
Protocol Posting of
Activations
Closures
Amendments, Revisions, Memoranda
Memorandum - Updated Master Forms Set
Prospective Evaluation of Carvedilol vs No treatment in Prevention of Cardiac Dysfunction in Patients with Metastatic HER-2+ Breast Cancer.
| Action Codes | NR |
| Study Coordinator(s) | Justin D. Floyd, D.O., Monika Leja, M.D., Carol Fabian, M.D., Andrew Godwin, Ph.D. |
| Participants | CTSU Institutions in the United States, ECOG-ACRIN, ALLIANCE, NRG |
Revision #3 - Version Date 4/23/2023
Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
| Action Codes | NR |
| Study Coordinator(s) | Melissa Accordino, M.D. |
| Participants | ALL NCORP COMPONENTS AND SUBCOMPONENTS, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - Participant Information Sheet (English) and Spanish Active Symptom Monitoring survey and documents available
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
| Study Coordinator(s) | Norah L. Henry, M.D.,Ph.D., Dawn Hershman, M.D., M.S. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required